PDCD1 and non-small cell lung carcinoma: Most notably, the phase II CITYSCAPE trial on locally advanced or metastatic non-small cell lung cancer demonstrated a nearly doubled overall response rate of combined anti-TIGIT/-PD-1 therapy compared to anti-PD-1 therapy alone [52].